Dr. Lucasti is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
730 Shore Rd
Somers Point, NJ 08244Phone+1 609-927-6662Fax+1 609-927-2942
Education & Training
Philadelphia College of Osteopathic MedicineClass of 1986
Certifications & Licensure
NJ State License 1988 - 2025
PA State License 1987 - 2020- AOA Board of Internal Medicine Infectious Disease
Clinical Trials
- Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® Start of enrollment: 2013 Feb 01
- Study of Debio 1450 for Bacterial Skin Infections Start of enrollment: 2015 May 01
- A Clinical Trial of STP0404 in Treatment-Naïve Adults With HIV-1 Infection Start of enrollment: 2023 May 23
Roles: Contact
Publications & Presentations
PubMed
- 16 citationsA Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program.Mark Redell, Greg Moeck, Christopher Lucasti, Stephanie Durso, Cynthia Kennedy
Open Forum Infectious Diseases. 2018-03-19 - 78 citationsEfficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controll...Richard Vickers, Glenn S. Tillotson, Richard Nathan, Sabine Hazan, John Pullman
The Lancet. Infectious Diseases. 2017-07-01 - 128 citationsPhase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal InfectionChristopher Lucasti, Liviu Vasile, Dorel Sandesc, Donatas Venskutonis, Patrick McLeroth
Antimicrobial Agents and Chemotherapy. 2016-09-23
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
